1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2020, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.
Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 20, 78, 56, 3, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 8 and 1 molecules, respectively.
Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Fallopian Tube Cancer - Overview
- Fallopian Tube Cancer - Therapeutics Development
- Fallopian Tube Cancer - Therapeutics Assessment
- Fallopian Tube Cancer - Companies Involved in Therapeutics Development
- Fallopian Tube Cancer - Drug Profiles
- Fallopian Tube Cancer - Dormant Projects
- Fallopian Tube Cancer - Discontinued Products
- Fallopian Tube Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Fallopian Tube Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Fallopian Tube Cancer - Pipeline by AB Science SA, H2 2020
- Fallopian Tube Cancer - Pipeline by AbbVie Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by ADC Therapeutics SA, H2 2020
- Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
- Fallopian Tube Cancer - Pipeline by AiVita Biomedical Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by Aldeyra Therapeutics Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by Amgen Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by Anew Oncology Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by Apexigen Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by Apollomics Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by Apotex Inc, H2 2020
- Fallopian Tube Cancer - Pipeline by Aravive Inc, H2 2020
- Fallopian Tube Cancer - Dormant Projects, H2 2020
- Fallopian Tube Cancer - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Fallopian Tube Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- AbbVie Inc
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- AiVita Biomedical Inc
- Aldeyra Therapeutics Inc
- Amgen Inc
- Anew Oncology Inc
- Apexigen Inc
- Apollomics Inc
- Apotex Inc
- Aravive Inc
- Arch Oncology Inc
- Arrien Pharmaceuticals LLC
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Basilea Pharmaceutica Ltd
- Bayer AG
- BeiGene Ltd
- Bio-Path Holdings Inc
- BioIntegrator Ltd
- BioNTech SE
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Celldex Therapeutics Inc
- Celsion Corp
- Celyad Oncology
- Clovis Oncology Inc
- Compugen Ltd
- Corcept Therapeutics Inc
- Cotinga Pharmaceuticals Inc
- Cristal Therapeutics BV
- Dr. Reddy's Laboratories Ltd
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- ENB Therapeutics LLC
- Esperance Pharmaceuticals Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fujifilm Holdings Corp
- Gene Techno Science Co Ltd
- Genentech USA Inc
- Genmab AS
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Gradalis Inc
- I-Mab
- ImmunityBio Inc
- Immunocore Ltd
- ImmunoGen Inc
- IMPACT Therapeutics Inc
- IMV Inc
- Incyte Corp
- Innovent Biologics Inc
- InSight Biopharmaceuticals Ltd
- InxMed Shanghai Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jina Pharmaceuticals Inc
- Johnson & Johnson
- Juno Therapeutics Inc
- Karyopharm Therapeutics Inc
- Kazia Therapeutics Ltd
- Kyowa Kirin Co Ltd
- Laekna Therapeutics Shanghai Co Ltd
- Leap Therapeutics Inc
- Legend Biotech Corp
- Lokon Pharma AB
- MabVax Therapeutics Holdings Inc
- MaxCyte Inc
- Merck & Co Inc
- Merck KGaA
- Mersana Therapeutics Inc
- Millennium Pharmaceuticals Inc
- Moderna Inc
- Mycenax Biotech Inc
- Northlake International LLC
- Novartis AG
- NuCana Plc
- Oasmia Pharmaceutical AB
- OBI Pharma Inc
- Omnitura Therapeutics Inc
- Oncoinvent AS
- Oncolytics Biotech Inc
- OncoQuest Inc
- Oncovir Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Pharma Mar SA
- PharmAbcine Inc
- Plexxikon Inc
- Precigen Inc
- Prestige BioPharma Pte Ltd
- PsiOxus Therapeutics Ltd
- PTC Therapeutics Inc
- R-Pharm US LLC
- Regeneron Pharmaceuticals Inc
- Rgenix Inc
- Richter Gedeon Nyrt
- Rigel Pharmaceuticals Inc
- Samyang Holdings Corp
- Sanofi
- SELLAS Life Sciences Group Inc
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shattuck Labs Inc
- Shenzen SiBiono GeneTech Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Sotio AS
- Sumitomo Dainippon Pharma Co Ltd
- Sumitomo Dainippon Pharma Oncology, Inc
- Sutro Biopharma Inc
- Synermore Biologics Co Ltd
- Tmunity Therapeutics Inc
- Transgene SA
